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Abstract
We have developed a simple method of generating scarless, unmarked mutations in Actinobacillus pleuropneumoniae by
exploiting the ability of this bacterium to undergo natural transformation, and with no need to introduce plasmids
encoding recombinases or resolvases. This method involves two successive rounds of natural transformation using linear
DNA: the first introduces a cassette carrying cat (which allows selection by chloramphenicol) and sacB (which allows
counter-selection using sucrose) flanked by sequences to either side of the target gene; the second transformation utilises
the flanking sequences ligated directly to each other in order to remove the cat-sacB cassette. In order to ensure efficient
uptake of the target DNA during transformation, A. pleuropneumoniae uptake sequences are added into the constructs used
in both rounds of transformation. This method can be used to generate multiple successive deletions and can also be used
to introduce targeted point mutations or insertions of heterologous genes into the A. pleuropneumoniae chromosome for
development of live attenuated vaccine strains. So far, we have applied this method to highly transformable isolates of
serovars 8 (MIDG2331), which is the most prevalent in the UK, and 15 (HS143). By screening clinical isolates of other serovars,
it should be possible to identify other amenable strains.
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Introduction
Porcine pleuropneumonia, caused by Actinobacillus pleurop-
neumoniae, is an endemic disease that continues to cause
considerable economic losses in the swine industry worldwide
[1,2]. After good husbandry practices are taken into account, there
are two basic methods used to limit endemic infection: vaccines
and antibiotics. Increasing resistance to antibiotics limits their
efficacy, and there is growing pressure against the use of antibiotics
in livestock production. Therefore development of an effective
vaccine is required for control of this important disease.
Although bacterin (killed whole cell) and subunit vaccines have
been developed for A. pleuropneumoniae, none has conferred
complete protection against infection with all serovars (for a
review, see [3]). There is growing interest in development of live
attenuated vaccines (LAVs), as they have the potential to protect
against homologous and heterologous serovars [4–6]. For licensing
purposes, a LAV should not contain antibiotic resistance markers,
and ideally should be easily differentiated from clinical isolates [5–
7]. Furthermore, an ideal LAV for A. pleuropneumoniae might
also be used as a vector for heterologous protection against other
pig pathogens.
At present, the only system for introducing unmarked mutations
into A. pleuropneumoniae is based on the use of suicide vectors
(pBMK1 and pEMOC2) carrying the counter-selectable sacB gene
[8,9]. First developed and most widely used in serovar 7 strain
AP76 [8–17], it has been successfully applied to selected strains of
serovars 1, 2, and 5 [6,7,18]. However, this system does not work
in all strains [7]. Because of the nature of the system, which
involves co-integration of the vector and formation of a
merodiploid, upon counter-selection, resolution of the integrated
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plasmid can result either in the strain retaining the mutated copy
of the target gene or in a return to the wild-type genotype.
Although there should be an equal likelihood of either result, this is
not always the case, and detection of the desired mutant strain
may require screening of large numbers of colonies.
We have previously reported that some strains of A.
pleuropneumoniae are capable of natural transformation [19,20].
The reference strains of serovars 1, 3, 4, 5 and 8 all showed low
frequencies of transformation (1028–1029), whereas the serovar 15
reference strain, HS143 [21], had a transformation frequency of
1024 [20]. Despite the low transformation frequency of the serovar
1 reference strain, Shope 4074, we and others, have used natural
transformation for generation of insertion-deletion mutations
[19,22–25]. Here we describe a simple two-step transformation
system using linear DNA for generation of unmarked mutations in
highly transformable isolates of A. pleuropneumoniae.
Materials and Methods
Bacterial strains and growth conditions
Escherichia coli XL1-Blue (Stratagene) or Stellar (Clontech),
used for plasmid construction, were propagated on Luria-Bertani
(LB; Difco) agar or in LB broth supplemented, when necessary,
with 20 mg/ml chloramphenicol (Cm) or 100 mg/ml ampicillin
(Amp). A. pleuropneumoniae serovar 8 (UK clinical isolates,
including MIDG2331) and serovar 15 (reference strain, HS143)
were grown at 37uC in 5% CO2 on brain heart infusion agar
(BHI; Difco) supplemented with 0.01% b-nicotinamide adenine
dinucleotide (BHI-NAD) or in BHI-NAD broth. When required,
1 mg/ml Cm was added for selection of transformants. For sucrose
counter-selection, bacteria were plated onto salt-free LB agar
consisting of 10 g tryptone, 5 g yeast extract, and 1.5 g agar per L
supplemented with 10% filter-sterilised sucrose (LB-S) for E. coli
clones, or onto salt-free LB agar supplemented with 10% sucrose,
10% horse serum and 0.01% NAD (LB-SSN) for A. pleuropneu-
moniae clones.
DNA manipulations
Genomic DNA was prepared from bacterial strains using a
QIAamp mini DNA kit, and plasmid extractions were performed
using Qiaprep spin columns (Qiagen), according to the manufac-
turer’s protocols. DNA concentrations were measured using a
NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop
Technologies). Unless otherwise stated, restriction enzymes were
obtained from Roche and used according to the manufacturer’s
protocol. PCR was performed using either the QIAGEN Fast
Cycling PCR Kit (Qiagen) or the CloneAmp HiFi PCR Premix
(Clontech), according to the manufacturers’ protocols.
Identification of highly transformable serovar 8 isolate(s)
In order to identify more highly transformable isolates of
serovar 8 of A. pleuropneumoniae, we tested 15 UK clinical
isolates (collected between 1992 and 2003 from different parts of
the UK) by the plate transformation assay previously described
[19]. Briefly, individual isolates were grown in BHI-NAD broth to
an OD600 of approximately 0.5, and 10 ml were spotted in
duplicate onto BHI-NAD agar (8 spots per plate). Strain HS143
(serovar 15 reference strain), previously shown to be highly
transformable [20], was used as a positive control. Following
100 min incubation at 37uC in 5% CO2, 750 ng of marked
genomic DNA (serovar 15 sodC::Cm) were added to one spot of
each strain (10 ml of 75 ng/ml), and cultures incubated for a
further 4 h. Using a 1 ml loop, a small amount of culture was
removed, bisecting each spot, and streaked for isolated colonies on
BHI-NAD-Cm. The selection plates were incubated overnight at
37uC in 5% CO2. Strains resulting in good growth on BHI-NAD-
Cm plates were tested further to determine transformation
frequency, as previously described [19].
Construction of the counter-selectable cassette
A 2.1 kb sequence containing the omlA promoter and sacB gene
was amplified by PCR from pBMK1 [8], a generous gift from
Professor Gerald-F. Gerlach, using primers sacB_For and
sacB_Rev (see Table 1 for all primers used in this study), which
added ApaI sites on both ends of the amplicon. The PCR product
was digested with ApaI, cleaned using a Qiaquick spin column
(Qiagen), and ligated using T4 DNA ligase (New England Biolabs)
into ApaI-digested pUSScat vector (a pGEMT plasmid containing
an 842 bp insert comprised of a cat gene flanked by 2 copies of the
uptake signal sequences (USS) required for natural transformation
in A. pleuropneumoniae [23,26]), which was dephosphorylated
using Shrimp Alkaline Phosphatase (Roche). The ligation mix was
transformed into E. coli XL1-Blue cells (Stratagene). Transfor-
mants were selected on LB-Cm, and screened by colony PCR for
the presence of the sacB gene. Sucrose sensitivity of selected clones
was confirmed by patching onto LB-S. Restriction mapping of the
pUSScatsac plasmid confirmed the insertion of the sacB gene
downstream of, and in the same orientation as, the cat gene.
Deletion of sodC and/or ureC
The primers used in creation of the constructs are shown in
Table 1. Where required, 15 bp extensions were added to the 59
end of primers to allow directional cloning of the PCR fragments
using the In-Fusion kit (Clontech) according to the manufacturer’s
protocol. The 3 kb cat-sacB cassette (Figure 1A) was amplified
from pUSScatsac using primers catsacB_for and catsacB_rev. As
mentioned above, this cassette contains 2 copies of the USS to
facilitate natural transformation in A. pleuropneumoniae. Flanking
sequences for the gene deletions were amplified from MIDG2331
chromosomal DNA using appropriate primer pairs. In cases where
the amplified A. pleuropneumoniae sequences did not contain
native USS, these were engineered into primers so that the
deletion constructs would be efficiently taken up in the second
transformation step. All fragments for the cat-sacB insertion and
deletion constructs were amplified using proof-reading CloneAmp
HiFi PCR Premix. Initially, PCR amplicons containing the genes
to be deleted (Figures 1B and 1C), flanked by at least 600–1000 bp
to either side, were cloned into pGEMT (Promega) to create
pTsodCF and pTureCF. Inverse PCR was then used to open up
the vectors, removing the target sequence and adding 15 bp
overhangs to allow insertion of the cat-sacB cassette by In-Fusion
cloning. The resulting In-Fusion products were transformed into
E. coli Stellar cells (Clontech) and were selected on LB agar
containing 20 mg/ml Cm, as required. PCRs were performed
using the QIAGEN Fast Cycling PCR Kit (Qiagen) on selected
colonies in order to confirm the presence of inserts. Selected cat-
sacB-containing clones were confirmed as being sensitive to
sucrose by patching onto LB-S plates. The deletion constructs
were generated by amplifying the left and right flanking sequences
with added 15 bp overhangs designed to allow direct fusion by
overlap-extension (OE) PCR. For example, the sodC flanking
regions were amplified using the primer pairs sodCleft_for/
deltasodC_left and deltasodC_right/sodCright_rev. The resulting
amplicons were combined, diluted 1/100, and used as template for
OE-PCR using the primer pair sodCleft_for/sodCright_rev. The
resulting deletion constructs were cloned into pGEMT.
Gene knockouts were achieved by two sequential transforma-
tion steps. In the first step, the plasmids containing the cat-sacB
Unmarked Mutations in Actinobacillus pleuropneumoniae
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cassette flanked by A. pleuropneumoniae-specific sequence were
linearised with NotI and transformed into the different A.
pleuropneumoniae strains by natural transformation on agar
plates, as previously described [19]. Cm-resistant transformants
were screened for the appropriate insertion-deletion by PCR, and
were tested for sensitivity to sucrose on LB-SSN. Subsequently,
deletion constructs (either purified OE-PCR products, or linear-
ised pGEMT clones containing the OE-PCR products) were used
to transform appropriate insertion-deletion mutants in order to
remove the cat-sacB cassette. Transformants were plated on LB-
SSN, and sucrose-resistant transformants were screened for Cm
sensitivity on BHI-NAD-Cm. Selected Cm-sensitive clones were
tested by PCR to confirm the appropriate deletion. The double
mutant (serovar 8 DsodCDureC) was obtained by transformation of
the serovar 8 DsodC mutant with linearised pTDureC::catsacB
construct, followed by removal of the cat-sacB cassette using the
linearised pTDureC construct in a second transformation. Loss of
urease activity was confirmed by addition of urea base medium
(Difco) to overnight broth cultures, as previously described [27].
Loss of SodC was confirmed by dot blot using the monoclonal
antibody HD1, as previously described [28].
Replacement of ureC with the Haemophilus ducreyi nadV
gene
A 1.5 kb sequence containing the nadV gene was amplified
from H. ducreyi genomic DNA (using primers listed in Table 1)
and was directionally cloned into the appropriate inverse PCR
product of pTDureCF (amplified using ureCnadV_left and
nadVureC_right as primers) using the In-Fusion kit. Following
transformation into E. coli Stellar cells, clones were screened by
PCR to identify the correct insertion. Plasmid prepared from a
selected clone was linearised with NotI prior to use as template
DNA to transform the sero8DureC::catsacB mutant in order to
remove the cat-sacB cassette. Sucrose resistant colonies were
screened for Cm-sensitivity and the ability to grow on BHI without
addition of NAD.
Results
Identification of a highly transformable serovar 8 isolate
Of the 15 UK clinical isolates tested, we identified one that had
a transformation frequency of 1.961025 (serovar 8 strain
MIDG2331). This transformation frequency is at least 3 logs
greater than previously shown for the serovar 8 reference strain
[20].
The unmarked mutation system
The cat-sacB cassette (Figure 1A) facilitated generation of
multiple successive mutations in A. pleuropneumoniae using the
two-step transformation protocol. Cm selection was very stringent,
and all Cm-resistant clones tested were confirmed to contain the
cat-sacB cassette by PCR (data not shown). Following counter-
selection after the second round of transformation, spontaneous
resistance to sucrose was evident, but the high transformation
frequencies for HS143 and MIDG2331 (1024 to 1025 for each
transformation) made it possible to isolate transformants and
confirm the deletion by PCR.
Deletion of sodC and/or ureC
As proof of principle, the two-step transformation system was
used to generate unmarked mutations of sodC and/or ureC in
serovars 8 and 15 of A. pleuropneumoniae. These genes (encoding
Table 1. Primers used in this study.
Name Sequence
sacB_for GCGTAATACGACTCACTATAGGGCCCATTG
sacB_rev TTCCGCTTCCTTTAGGGGCCCTTG
catsacB_for GATTCGCGGATCCGAGCTCTCTAAC
catsacB_rev GCGTGAAGCTCGAGGTATGGGATTC
sodCleft_for GGATTCGCCAATaCCGCTTGtACG
sodCright_rev CCTTATTAAATGGCGGACCGACTTTCC
sodCcat_left TCGGATCCGCGAATCGATGCGCCGAATAATGTAAAAGCAAGAG
sacBsodC_right CCTCGAGCTTCACGCGGCTTGCGGCGTCATCAAATAGC
deltasodC_left ATGACGCCGCAAGCCGATGCGCCGAATAATGTAAAAGCAAGAG
deltasodC_right ATTATTCGGCGCATCGGCTTGCGGCGTCATCAAATAGC
ureCleft_for CGGTCATAAaCAAGCGGTCTATTTTCAG
ureCright_rev GATTGTGCCGATATTGAGTTCTGTACCAAAC
ureCcat_left TCGGATCCGCGAATCCCATTTTCTGCCCCCTATAATTTGC
sacBureC_right CCTCGAGCTTCACGCCGTGTGGACGGCGAGCATATTACTTG
deltaureC_left CTCGCCGTCCACACGCCATTTTCTGCCCCCTATAATTTGC
deltaureC_right GGGGGCAGAAAATGGCGTGTGGACGGCGAGCATATTACTTG
ureCnadVleft GGGCTCGGTTACTAGCCATTTTCTGCCCCCTATAATTTGC
nadVureC_right ACTCGTGCGGCCGCCCGTGTGGACGGCGAGCATATTACTTG
nadV_for CTAGTAACCGAGCCCGCCTAATGAG
nadV_rev GGCGGCCGCACTAGTGATTACAAG
ApaI sites in the sacB_for and sacB_rev primers are underlined. The USS present in sodCleft_for and ureCleft_for are indicated in italics with the lower case letters
indicating a base change from the native sequence in order to generate a USS. The 15-bp extensions required for In-Fusion cloning are indicated in bold text.
doi:10.1371/journal.pone.0111252.t001
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a [Cu,Zn]-superoxide dismutase and a subunit of the urease
enzyme, respectively) were chosen because they are present in all
A. pleuropneumoniae serovars and have easily detectable pheno-
types. Deletion of sodC and/or ureC was confirmed in the different
strains as shown by PCR (Figure 1D), SodC dot blot (Figure 2A),
and urease activity assay (Figure 2B), as appropriate.
Replacement of ureC with the H. ducreyi nadV gene
In order to illustrate the usefulness of this method for
introducing foreign genes into targeted locations in the chromo-
some of A. pleuropneumoniae, a portion of the ureC gene was
replaced with the H. ducreyi nadV gene. The nadV gene was
chosen as heterologous expression from a plasmid was previously
shown to result in NAD-independence in A. pleuropneumoniae
[29], making it easy to phenotypically verify the insertion following
sucrose counterselection. Expression of the chromosomally insert-
ed nadV gene rendered A. pleuropneumoniae strains NAD-
independent (Figure 2C), while elimination of urease activity in
the mutant (Figure 2B), along with PCR verification (Figure 1D),
confirmed the targeted location of the insertion.
Figure 1. Construction and PCR verification of sodC and ureC deletions. A) Map showing the 3.0 kb cat-sacB cassette amplified from
pUSScatsac using using catsacB_for and catsacB_rev. Triangles above the map indicate positions of the 2 USS required for efficient transformation,
the bent arrow indicates the position of the omlA promoter. B) Map showing 2.1 kb sequence amplified using sodCleft_for and sodCright_rev (cloned
into pTsodCF). Arrows above the map indicate positions of primers used in inverse PCR to delete a 504 bp region of sodC, and to add 15-bp
overhangs required for fusion to the cat-sacB cassette (sodCcat_left and sacBsodC_right) or for direct fusion of the left and right flank sequences
(deltasodC_left and deltasodC_right). C) Map showing the 3.2 kb sequence amplified using ureCleft_for and ureCright_rev (cloned into pTureCF).
Arrows above the map indicate positions of primers used in inverse PCR to delete a 1641 bp region of ureC, and to add 15-bp overhangs required for
fusion to the cat-sacB cassette (ureCcat_left and sacBureC_right), for direct fusion of the left and right flank sequences (deltaureC_left and
deltaureC_right), or fusion to a 1914 bp fragment containing the nadV gene from H. ducreyi (ureCnadVleft and nadVureC_right). D) PCR amplification
using primers sodCleft_for and sodCright_rev (lanes 1–6) or ureCleft_for and ureCright_rev (lanes 7–10) with template DNA from: 1) sero 15 WT; 2)
sero 15 DsodC; 3) sero 8 WT; 4) sero 8 DsodC; 5) sero 8 DsodCDureC; 6) sero 8 DureC; 7) sero 8 WT; 8) sero 8 DureC; 9) sero 8 DsodCDureC; 10) sero 8
DureC::nadV. M = 1 kb DNA ladder (Invitrogen).
doi:10.1371/journal.pone.0111252.g001
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Discussion
The introduction of unmarked mutations into the bacterial
chromosome is particularly desirable for generation of multiple
mutations and LAVs. In A. pleuropneumoniae, suicide vectors
(pBMK1 and pEMOC2) have been used by some groups to
generate (multiple) unmarked mutations in selected strains
[5,6,7,18]. In our experience, however, although co-integrates
are readily selected following conjugation of constructs based on
these plasmids, counter-selection on sucrose tends to yield high
numbers of wild-type revertants, making identification of true
deletion mutants extremely laborious and often impossible.
Recently, a markerless mutation system was described for
Actinobacillus succinogenes [30]. The method used a combination
of natural transformation for introduction of insertion/deletion
mutations with FRT sites flanking the selective marker, and
electroporation with a plasmid expressing the Flp recombinase to
drive excision of the marker. This method leaves a residual FRT
site (scar) with each deletion, and requires curing of the plasmid
expressing the recombinase. Although multiple successive muta-
tions are possible, the build up of FRT scars in the chromosome
could lead to recombination hotspots, which would not be
desirable in a LAV strain.
Previously, we have shown the utility of natural transformation
for generation of insertion-deletion mutations in A. pleuropneu-
moniae using linear dsDNA constructs [19,23,25]. By adding a
counter-selectable gene into the insertion-deletion cassette and a
second transformation step to remove the cassette, we have further
exploited this simple technique to generate scarless unmarked
deletions, and to insert a heterologous gene into a targeted site in
the chromosome. This method can also be used for the generation
of targeted point mutations by incorporating these into the
unmarked sequence used in the second transformation step. The
use of linear DNA templates (either linearised plasmid or PCR
product) in both rounds of transformation ensures that allele
replacement is by double-crossover, avoiding problems associated
with merodiploid formation/resolution that can arise with suicide
vectors. Furthermore, DNA taken up by natural transformation is
not prone to degradation by the abundant restriction systems
present in A. pleuropneumoniae, which can affect efficiency of
electroporation [31].
A similar two-step natural transformation method has been
described for creating unmarked mutations in Helicobacter pylori
[32] and Acinetobacter sp. strain ADP1 [33], transformable
bacteria that do not require specific USS. When creating mutants
in A. pleuropneumoniae by this method, it is essential to include
the 9 bp USS (ACAAGCGGT) required for efficient uptake of
DNA by this bacterium [20,26] in donor DNA used in both steps.
To this end, we have generated a cat-sacB cassette containing 2
perfect copies of the A. pleuropneumoniae USS flanking the cat
gene. This ensures efficient uptake of the insertion-deletion
construct. In the second step, if the unmarked deletion fragment
does not contain an endogenous USS, then it can be engineered
into primer sequence(s), as we have done.
In this study, we have generated mutations in the highly
transformable serovar 15 reference strain HS143 [21], as well as in
the serovar 8 clinical isolate MIDG2331. We chose serovar 8 to
reflect its high prevalence in the UK [34]. MIDG2331, amenable
to this method of creating unmarked deletions, was identified after
screening only 15 isolates. In countries where other serovars
predominate, we recommend testing a selection of clinical isolates
for identification of appropriate transformable strains. Testing
must be empirical, as the presence of known competence genes is
not sufficient to ensure successful transformation of A. pleur-
opneumoniae strains [20]. Even in Haemophilus influenzae, where
natural transformation has been extensively studied, the reason for
variation in levels of competence of different isolates is not clear
[35].
With the availability of whole genome sequences for most
serovars of A. pleuropneumoniae [36–39], it is now possible, using
HS143 and/or MIDG2331, to systematically mutate specific
highly conserved core genes in order to determine their
contribution to the biology and pathogenesis of this bacterium,
with a view to improving diagnostics, therapies and vaccine
strategies.
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